4'-Fluoro Nucleosides for HCV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infections lack effective and low-toxicity pharmaceutical agents, and there is a need for new treatments that can address the rising threat of flaviviridae infections.
Innovation Solution
Development of 4′-fluoro nucleosides, which are administered alone or in combination with other anti-Flaviviridae agents, to treat HCV and related conditions by targeting RNA-dependent RNA polymerase viruses, including HCV, through specific compounds represented by formulas such as 1501, 1001, and I, with various modifications to enhance efficacy and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for HCV are used, then treatment coverage is provided, but efficacy and bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleoside analogs through fluorine substitution at the 4' position and varying substituent groups (R1-R6, Ar1-Ar3). These structural parameter changes enhance both the efficacy and bioavailability of the compounds while maintaining their ability to inhibit HCV RNA polymerase, directly resolving the contradiction between treatment reliability and productivity
2Reliability
If existing anti-HCV agents are administered, then viral infection is targeted, but toxicity to the host increases
Solution Approach 1:
The patent applies local quality by introducing specific fluorine substitution at the 4' position of the nucleoside ring and incorporating particular substituent patterns (such as fluorinated aryl groups and specific heterocyclic moieties). These localized structural modifications enhance anti-viral activity through improved binding to the viral polymerase while reducing off-target effects and host toxicity, thereby resolving the contradiction between reliability and harmful factors
3Reliability
If new effective agents are developed, then treatment efficacy improves, but complexity of compound structure increases
Solution Approach 1:
The patent applies universality by designing a core nucleoside scaffold with fluorine substitution that maintains a consistent mechanism of action (inhibition of RNA-dependent RNA polymerase) across multiple compounds. This universal core structure allows for systematic variation of substituents to optimize efficacy without proportionally increasing complexity, enabling the development of multiple effective agents with manageable structural complexity
Data Source
AI summary
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501:or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.